Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

The fast diffusion of the SARS-CoV-2 pandemic have called for an equally rapid evolution of the therapeutic options. The Human recombinant monoclonal antibodies (mAbs) have recently been approved by the Food and Drug Administration (FDA) and by the Italian Medicines Agency (AIFA) in subjects aged ≥1...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanari, Marcello, Venturini, Elisabetta, Pierantoni, Luca, Stera, Giacomo, Castelli Gattinara, Guido, Esposito, Susanna Maria Roberta, Favilli, Silvia, Franzoni, Emilio, Fusco, Eleonora, Lionetti, Paolo, Maffeis, Claudio, Marseglia, Gianluigi, Massella, Laura, Midulla, Fabio, Zanobini, Alberto, Zecca, Marco, Villani, Alberto, Staiano, Annamaria, Galli, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754075/
https://www.ncbi.nlm.nih.gov/pubmed/35022088
http://dx.doi.org/10.1186/s13052-021-01187-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754075/
https://www.ncbi.nlm.nih.gov/pubmed/35022088
http://dx.doi.org/10.1186/s13052-021-01187-1

Ejemplares similares